Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

Inclusion criteria

• Histologically or cytologically confirmed advanced solid tumors who have progressed despite standard therapy, or for whom no standard therapy exists, or who might benefit from treatment with carboplatin
• A minimum of 4 weeks since the last treatment with chemotherapy
• WHO Performance Status 0 (able to carry out all normal activity without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work)
• Age ≥ 18
• Adequate hematological parameters
• No major impairment of renal or hepatic function
• Written informed consent obtained

Exclusion criteria

• Major surgery less than 4 weeks prior to study entry and/or not fully recovered from surgery
• Chemotherapy or investigational compound less than 4 weeks prior to study entry, or planned while participating in the study
• Prior administration of an epothilone
• Hypersensitivity to carboplatin. Patients resistant to carboplatin are not recommended to enter the trial
• Radiotherapy (RT) less than 4 weeks prior to study entry (except for palliative therapy of distant metastases), or planned RT while participating in the study
• Diarrhea within 7 days prior to start of treatment. Unresolved bowel obstruction
• Peripheral neuropathy > Grade 1 (mild)
• Symptomatic brain metastases
• Colostomy

Other protocol-defined inclusion/exclusion criteria may apply